NR1H4 and myocardial ischemia: GW4064, an agonist of FXR, has been reported to activate permeability transition pores and promote cytochrome c release together with stimulation of caspase-9 and caspase-3 in myocardial ischemia/reperfusion injury, resulting in worsened outcomes [8, 9].